HOME >> MEDICINE >> NEWS
LSUHSC neurosurgical team discovers novel therapy for intractable hiccups

New Orleans--Dr. Bryan R. Payne, and Dr. Robert Tiel, neurosurgeons at LSU Health Sciences Center in New Orleans have discovered a new approach to treating medically intractable hiccups. They implanted a Vagus Nerve Stimulator in a Texas man to stop the hiccups which have severely disrupted Shane Shafer's life following a stroke he had two years ago. This is the first reported case of its kind. When Dr. Payne activated the implant following the surgery, Shafer's hiccups stopped, and they have not as yet returned.

Although hiccups are a normal occurrence, they serve no useful purpose. Hiccups are normally self-limiting. In some cases, however, hiccups don't go away, and these prolonged attacks can cause significant illness and even death. When the attack lasts longer than a month, the hiccups are termed intractable. Although more than a hundred causes have been describedeverything from hysteria to trauma and malignancies--sometimes hiccups are caused by irritation of the vagus nerve. The vagus nerve, measuring about 22 inches, is the longest cranial nerve, wandering throughout the upper body. It is one of the body's primary communication pathways from the brain to other organs, and it contains few if any pain fibers. Mr. Shafer's hiccups were likely due to an aberrant connection or cycle between the groups of brain cells associated with the vagus nerve and those of the phrenic nerve which supplies the diaphragm caused by his stroke.

A vagus nerve stimulator uses electrical impulses delivered by a programmable generator implanted in the chest to two tiny leads wrapping around the vagus nerve in the neck to disrupt faulty nerve communication. The "dose" of stimulation, programmed by the physician, is automatically delivered. VNS therapy has been effective in controlling medically refractory seizures, and an FDA Advisory panel recently recommended approval of VNS therapy as an adjunct treatment for non-responsive depression as well. The minimally invasive pro
'"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Science Center
24-Jun-2004


Page: 1 2

Related medicine news :

1. LSUHSC microsurgeon performs 1st ever eyelid reattachment
2. Mayo Clinic discovers new pathway against pancreatic cancer
3. Mayo Clinic discovers a key to low metabolism and major factor in obesity
4. Mayo Clinic discovers potential marker for aggressive kidney cancer
5. Mayo Clinic discovers one mechanism for why men and women differ in immune response
6. Mayo Clinic discovers important clue to new treatments for lymphoma, breast and colon cancers
7. UCSF-led team discovers possible cancer susceptibility gene
8. Mayo Clinic discovers one more downside to alcoholism
9. Study discovers a way to keep infants safe from second-hand smoke
10. Baylor team discovers reason for heart transplant failure
11. Mayo Clinic discovers cause of a frequently fatal myasthenic syndrome affecting children

Post Your Comments:
(Date:5/22/2013)... WEDNESDAY, May 22 (HealthDay News) -- Roughly four in ... obstructive pulmonary disease (COPD) actually do not have the ... issue: Faulty diagnoses were made based on an evaluation ... "gold standard" disease test known as spirometry, which shows ... the amount of air they can exhale and how ...
(Date:5/22/2013)... New research from Brigham and Women,s Hospital (BWH) finds ... uncommon but deadly lung disease, may be effective in ... findings will be presented at the American Thoracic Society ... New England Journal of Medicine on May 22 ... edition., "While this variant of the MUC5B gene is ...
(Date:5/22/2013)... ATS 2013, PHILADELPHIA ─More than 40 percent of ... funded clinic did not have the disease, researchers ... diagnostic "gold standard" for chronic obstructive pulmonary disease. ... the under-diagnosis of COPD, there has not been ... of over-diagnosis," said Christian Ghattas, MD., MSc, ...
(Date:5/22/2013)... In the past decade, more ... courts with donated uniforms, shoes, balls and other ... to partnering with manufacturers to provide youth with sporting ... $8.8 million in sports and fitness equipment over 10 ... outfitted for physical activity. , An inaugural donation ...
(Date:5/22/2013)... Alabama (PRWEB) May 22, 2013 ... solutions to state Health and Human Services and ... of Mental Health (ADMH) selected the CoCENTRIX ... platform to manage the Health Records and coordinate ... psychiatric hospitals. , CoCENTRIX is transitioning the ...
Breaking Medicine News(10 mins):Health News:COPD May Be Over-Diagnosed Among Uninsured 2Health News:Genetic marker associated with risk for pulmonary fibrosis 2Health News:Study finds COPD is over-diagnosed among uninsured patients 2Health News:Study finds COPD is over-diagnosed among uninsured patients 3Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 2Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 3Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 2Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 3
(Date:5/22/2013)... 22, 2013  Grifols, a global healthcare company based ... from a study demonstrating that a higher dose of ... levels of the alpha 1 protein in patients ... are considered within the normal range for healthy individuals. ... low levels of the alpha 1 proteinase inhibitor ...
(Date:5/22/2013)...  BD (Becton, Dickinson and Company) (NYSE: ... today the publication of its 2012 Sustainability Report ... continues to focus on the Company,s shared value approach ... of shared value — creating value for shareholders by ... are fundamental to our strategy," said Vincent ...
(Date:5/22/2013)... Calif. , May 22, 2013 Rigel ... the clinical advancement of three programs in development. The ... a JAK/SYK inhibitor, R348, being developed by Rigel as ... programs are aimed at oncology targets and are being ... under development by BerGenBio AS (BerGenBio) and a ligase ...
Breaking Medicine Technology:Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4BD Issues 2012 Sustainability Report 2BD Issues 2012 Sustainability Report 3Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 2Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 3Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 4
Cached News: